Results from a Phase II Trial of Pembrolizumab in Relapsed/Refractory CLL, Including in Patients with Richter’s Transformation


Results from a Phase II Trial of Pembrolizumab in Relapsed/Refractory CLL, Including in Patients with Richter’s Transformation
Slides from a presentation at ASH 2015 and transcribed comments from a recent interview with Jeff Sharman, MD (2/9/16)

Ding W et al. PD-1 blockade with pembrolizumab (MK-3475) in relapsed/refractory CLL including Richter transformation: An early efficacy report from a Phase 2 trial (MC1485). Proc ASH 2015;Abstract 834.

Dr Sharman is Director of Research at the Willamette Valley Cancer Institute and Medical Director of Hematology Research at The US Oncology Network in Eugene, Oregon.